VANCOUVER, British Columbia, April 24, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its wholly owned subsidiary Vocan, has entered into a Collaborative Research Agreement with the University of British Columbia (“UBC” or the “University”). Research will be conducted in a 10,000 square foot well-equipped, technologically diverse and well funded lab located at the Lower Mall Research Station at the University. The Research Faculty has an extensive team including a principal investigator, Post-Doctoral fellows, lab manager, research technicians, and research associates.The collaboration gives the company access to cutting edge research facilities and innovation capabilities at UBC. The UBC research team’s history of strong research and development efforts provides an opportunity for Vocan to accelerate its position as a powerful player in the emerging psychedelic medicines space. Psychedelic compounds have recently transitioned into the mainstream medicine market. Psilocybin, MDMA and LSD have shown significant therapeutic benefits when it comes to addressing depression, anxiety, addiction and obsessive-compulsive disorder.The collaboration with UBC will assist Vocan in individually optimizing the expression of enzymes allowing the production of the prodrug psilocybin from the Psilocybe genus of mushrooms. Vocan will supply its developed technology, and the UBC lab will utilize its proven expertise to optimally express critical enzymes to enable their recombinant synthesis in a suitable bacteria host. This will increase the efficiency and cost effectiveness of the process and assist Vocan scientists in enabling the production of psilocybin using fermentation. Using bacteria as “biological factories” in this way is a well-established method for producing commercial products, having been employed for insulin and human growth hormone, but needs to be individually optimized for each product.“The collaboration with UBC Research Faculty enables Vocan to fast track its production method of biosynthesized psilocybin. The state-of-the-art equipment will allow for enhanced analysis of the compound, and the additional personnel exponentially increases the capacity of Vocan’s Research Team,” stated Joel Shacker CEO of the Company.About UBC
The University of British Columbia was established in 1908, is the largest university in Western Canada and has an annual research budget of $600,000,000.00. It is ranked in the top 3 universities in Canada and is 27th in the world for academic ranking. The University has a history of producing esteemed graduates, including 3 Canadian Prime Ministers, including Justin Trudeau, 8 Nobel Laureates, 71 Rhodes scholars, 65 Olympians, and 273 fellows to the Royal Society of Canada. UBC has an academic staff of 5500, over 50,000 Undergraduate students and 10,000 Postgraduate students.About Core One Labs Inc.Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.Core One Labs Inc.Joel ShackerChief Executive OfficerFOR MORE INFORMATION, PLEASE CONTACT: firstname.lastname@example.org 1-866-347-5058
Cautionary Disclaimer Statement: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
PISCATAWAY, N.J., April 23, 2021 /PRNewswire/ -- MSN Labs, based in Hyderabad, India, received FDA approval to market their generic versions of Albendazole 200mg tablets (AB rated to Albenza©), Droxidopa 100mg, 200mg, 300mg capsules (AB rated to Northera ©), Deferasirox Granules 180mg, 360mg sachets (AB rated to Jadenu Sprinkles©) and Pregabalin ER 82.5mg, 165mg, 330mg tablets, (AB rated to Lyrica CR©) under the Novadoz label. Novadoz is the U.S sales and marketing affiliate for MSN's portfolio of finished dosage forms. The company has commenced shipping of all the products which received approvals during Q1 2021.Albendazole 200mg is marketed in bottles of 2 tablets. It is indicated for the treatment of neurocysticercosis which is an infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems. The most recent 12 month published sales of the brand and generics total $26.9mil.Droxidopa 100mg, 200mg, & 300mg are available in bottles of 30 capsules. It is indicated for the symptomatic treatment of dizziness, lightheadedness, or fainting/black out sensation due to neurogenic orthostatic hypotension (a sudden fall in blood pressure). Novadoz participated in a Day 1 launch of the product, coinciding with the expiration of the brand exclusivity. Previous 12 month published sales for the brand totaled $366mil. Novadoz has also offered a patient e-voucher assistance plan for those qualified consumers needing aid to cover their out of pocket prescription co-pay costs for Droxidopa. Visit NovadozPharma.com to learn more information on the program.Among their recent FDA approvals include niche products, Deferasirox Granules 180mg, and 360mg that are available in a carton of 30 sachets. The product is used treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions. The other niche offering includes Pregabalin ER 82.5mg, 165mg, and 330mg tablets available in bottles of 30. The product is indicated for the treatment of pain caused by nerve damage due to diabetes or shingles (herpes zoster).
Seshu Akula, Novadoz President North America Generics, states, "The first quarter of 2021 was a very active period for the MSN/Novadoz organization with four FDA approvals. We successfully introduced these products to the market, while keeping pace with the high demand for our existing product line created by the pandemic."He adds, "MSN's position as a global leader in APIs has provided Novadoz with the scale and leveraged strength comparable to some of the largest generic pharma companies in the U.S. We are well positioned in the generic industry with a deep pipeline of oral solids, injectable, and specialty products that we expect to launch over the next 10 years."MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates. MSN is a global leader in this category. Additionally, the company also manufactures oral solids, liquids, and specialty injectable products in sixty-five markets throughout the world, doing business in the U.S. as Novadoz Pharmaceuticals.For more information, visit the company's websites at NovadozPharma.com & MSNLabs.com.CONTACT:Tom DeStefanoNovadoz Pharmaceuticals Vice President Sales and Marketing (848) 200-1909
View original content to download multimedia:https://www.prnewswire.com/news-releases/novadoz-has-a-fast-start-to-2021-with-generic-launches-of-albendazole-droxidopa-deferasirox-granules-and-pregabalin-er-301275804.htmlSOURCE Novadoz Pharmaceuticals
MyPillow CEO Mike Lindell waits outside the West Wing of the White House on January 15, 2021 in Washington, DC.
Photo by Drew Angerer/Getty Images